Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy?

AIDS. 2011 Jul 17;25(11):1430-3. doi: 10.1097/QAD.0b013e328349060e.

Abstract

Secondary hyperparathyroidism may develop in the presence of hypovitaminosis D in order to maintain calcium homeostasis. We conducted a cross-sectional analysis in a cohort of 371 patients, identifying secondary hyperparathyroidism in 65 patients. This high prevalence (17.5%) was in part justified by the high prevalence of hypovitaminosis D (77.4%) in the whole sample, but we also identified an independent association with the use of tenofovir.

MeSH terms

  • Absorptiometry, Photon
  • Adult
  • Aged
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Biomarkers
  • Bone Density / drug effects*
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Hyperparathyroidism, Secondary / chemically induced*
  • Hyperparathyroidism, Secondary / epidemiology
  • Hyperparathyroidism, Secondary / metabolism
  • Male
  • Middle Aged
  • Prevalence

Substances

  • Biomarkers